CMRX vs. VSTM, FBIO, SCPH, CHMA, AQST, VTYX, NKTX, XERS, NBTX, and SKYE
Should you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include Verastem (VSTM), Fortress Biotech (FBIO), scPharmaceuticals (SCPH), Chiasma (CHMA), Aquestive Therapeutics (AQST), Ventyx Biosciences (VTYX), Nkarta (NKTX), Xeris Biopharma (XERS), Nanobiotix (NBTX), and Skye Bioscience (SKYE). These companies are all part of the "medical" sector.
Chimerix (NASDAQ:CMRX) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, community ranking, earnings, risk, valuation and profitability.
In the previous week, Chimerix had 1 more articles in the media than Verastem. MarketBeat recorded 3 mentions for Chimerix and 2 mentions for Verastem. Chimerix's average media sentiment score of 0.96 beat Verastem's score of 0.00 indicating that Chimerix is being referred to more favorably in the media.
Chimerix has higher earnings, but lower revenue than Verastem. Chimerix is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
Chimerix has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.
45.4% of Chimerix shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 13.1% of Chimerix shares are owned by company insiders. Comparatively, 2.2% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Chimerix currently has a consensus target price of $8.50, suggesting a potential upside of 810.55%. Verastem has a consensus target price of $25.69, suggesting a potential upside of 655.51%. Given Chimerix's higher probable upside, equities analysts clearly believe Chimerix is more favorable than Verastem.
Verastem has a net margin of 0.00% compared to Chimerix's net margin of -25,337.96%. Chimerix's return on equity of -41.32% beat Verastem's return on equity.
Verastem received 212 more outperform votes than Chimerix when rated by MarketBeat users. Likewise, 65.28% of users gave Verastem an outperform vote while only 63.59% of users gave Chimerix an outperform vote.
Summary
Chimerix beats Verastem on 10 of the 17 factors compared between the two stocks.
Get Chimerix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chimerix Competitors List
Related Companies and Tools
